Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment

References

• de MurciaJMNiedergangCTruccoCRequirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cellsProc Natl Acad Sci U S A19979414730373079207086
   PubMed Web of Science ®Google Scholar
• WangZQStinglLMorrisonCPARP is important for genomic stability but dispensable in apoptosisGenes Dev19971118234723589308963
   PubMed Web of Science ®Google Scholar
• FarmerHMccabeNLordCJTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature2005434703591792115829967
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• YapTASandhuSKCardenCPde BonoJSPoly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinicCA Cancer J Clin2011611314921205831
   PubMed Web of Science ®Google Scholar
• DantzerFde La RubiaGMénissier-de MurciaJHostomskyZde MurciaGSchreiberVBase excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1Biochemistry200039257559756910858306
   PubMed Web of Science ®Google Scholar
• AshworthAA synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repairJ Clin Oncol200826223785379018591545
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYDasBBTrapping of PARP1 and PARP2 by clinical PARP inhibitorsCancer Res201272215588559923118055
   PubMed Web of Science ®Google Scholar
• MuraiJHuangSYRenaudAStereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparibMol Cancer Ther201413243344324356813
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLGynecologic Oncology GroupIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med20063541344316394300
   PubMed Web of Science ®Google Scholar
• YapTACardenCPKayeSBBeyond chemotherapy: targeted therapies in ovarian cancerNat Rev Cancer20099316718119238149
   PubMed Web of Science ®Google Scholar
• IhnenMZu EulenburgCKolarovaTTherapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancerMol Cancer Ther20131261002101523729402
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialLancet Oncol201415885286124882434
   PubMed Web of Science ®Google Scholar
• DonawhoCKLuoYLuoYABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor modelsClin Cancer Res20071392728273717473206
   PubMed Web of Science ®Google Scholar
• EversBDrostRSchutESelective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatinClin Cancer Res200814123916392518559613
   PubMed Web of Science ®Google Scholar
• DhawanMSAggarwalRRBartelinkIEfficacy and hematologic toxicity of carboplatin and talazoparib combination therapy in BRCA mutated patientsJ Clin Oncol20163415_suppl255727185839
   PubMed Web of Science ®Google Scholar
• LandrumLMBradyWEArmstrongDKA phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab, and veliparib (ABT-888) in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: a Gynecologic Oncology Group studyGynecol Oncol201513722325643690
   PubMedGoogle Scholar
• RajanACarterCAKellyRJA phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumorsClin Cancer Res20121882344235122371451
   PubMed Web of Science ®Google Scholar
• BalmañaJTungNMIsakoffSJPhase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumorsAnn Oncol201425817117824299961
   PubMed Web of Science ®Google Scholar
• SamolJRansonMScottESafety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I studyInvest New Drugs20123041493150021590367
   PubMed Web of Science ®Google Scholar
• LeeJ-MHaysJLAnnunziataCMPhase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJ Natl Cancer Inst20141066111
   Google Scholar
• TuttARobsonMGarberJEOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialLancet2010376973723524420609467
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• De JongWHBormPJDrug delivery and nanoparticles: applications and hazardsInt J Nanomedicine20083213314918686775
   PubMed Web of Science ®Google Scholar
• MaedaHThe enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targetingAdv Enzyme Regul20014118920711384745
   PubMedGoogle Scholar
• ArmstrongDKBundyBWenzelLIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med20063541344316394300
   PubMed Web of Science ®Google Scholar
• MateoJMorenoVGuptaAAn adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparibTarget Oncol201611340141527169564
   PubMed Web of Science ®Google Scholar
• van de VenALTangutooriSBaldwinPNanoformulation of olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiationMol Cancer Ther20171671279128928500233
   PubMed Web of Science ®Google Scholar
• BanghamADStandishMMWatkinsJCDiffusion of univalent ions across the lamellae of swollen phospholipidsJ Mol Biol19651312382585859039
   PubMed Web of Science ®Google Scholar
• PeretsRWyantGAMutoKWTransformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten modelsCancer Cell201324675176524332043
   PubMed Web of Science ®Google Scholar
• DinulescuDMInceTAQuadeBJShaferSACrowleyDJacksTRole of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancerNat Med2005111637015619626
   PubMed Web of Science ®Google Scholar
• BaldwinPTangutooriSSridharSGeneration of Dose -Response Curves and Improved IC50s for PARP Inhibitor NanoformulationsMethods Mol Biol2017153033734228150212
   PubMedGoogle Scholar
• RottenbergSJaspersJEKersbergenAHigh sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProc Natl Acad Sci U S A200810544170791708418971340
   PubMed Web of Science ®Google Scholar
• ShenWHBalajeeASWangJEssential role for nuclear PTEN in maintaining chromosomal integrityCell2007128115717017218262
   PubMed Web of Science ®Google Scholar
• Mendes-PereiraAMMartinSABroughRSynthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Mol Med200916–731532220049735
   PubMed Web of Science ®Google Scholar
• ModiSAndersonBDDetermination of drug release kinetics from nanoparticles: overcoming pitfalls of the dynamic dialysis methodMol Pharm20131083076308923758289
   PubMed Web of Science ®Google Scholar
• RicksTKChiuHJIsonGSuccesses and challenges of PARP inhibitors in cancer therapyFront Oncol2015522226528434
   PubMed Web of Science ®Google Scholar
• FarzanehFZalinRBrillDShallSDNA strand breaks and ADP-ribosyl transferase activation during cell differentiationNature198230058903623666292727
   PubMed Web of Science ®Google Scholar
• Drugs@FDA, FDA Approved Drug ProductsLYNPARZA. Pharmacology Review. US Food and Drug Administration, Center for Drug Evaluation and Research Web site Available form: http://www.access-data.fda.gov/scripts/cder/drugsatfdaAccessed November 1, 2018
   Google Scholar
• BajajGYeoYDrug delivery systems for intraperitoneal therapyPharm Res201027573573820198409
   PubMed Web of Science ®Google Scholar
• KohaneDSTseJYYeoYPaderaRShubinaMLangerRBiodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneumJ Biomed Mater Res A200677235136116425240
   PubMed Web of Science ®Google Scholar
• MaedaHToward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneityAdv Drug Deliv Rev2015913625579058
   PubMed Web of Science ®Google Scholar
• PrabhakarUMaedaHJainRKChallenges and key considerations of the enhanced permeability and retention effect for nanomedi-cine drug delivery in oncologyCancer Res20137382412241723423979
   PubMed Web of Science ®Google Scholar
• DengYYangFCoccoEImproved i.p. drug delivery with bioadhesive nanoparticlesProc Natl Acad Sci U S A201611341114531145827663731
   PubMed Web of Science ®Google Scholar
• WangLMaJLiuFExpression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significanceGynecol Oncol2007105369570217368732
   PubMed Web of Science ®Google Scholar
• KalliKRObergALKeeneyGLFolate receptor alpha as a tumor target in epithelial ovarian cancerGynecol Oncol2008108361962618222534
   PubMed Web of Science ®Google Scholar
• QinYSongQGZhangZROvarian tumor targeting of docetaxel-loaded liposomes mediated by luteinizing hormone-releasing hormone analoguesArzneimittelforschung20115810529534
   Google Scholar